These findings suggest that the anti-novel-miR-7 sequence has the therapeutic potential for CMD during NAFLD by regulating LAMP1/Cathepsin B/NLRP3 inflammasome axis. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatotic liver disease.